Therapy of rituximab-refractory rheumatoid arthritis patients

Details Therapy of rituximab-refractory rheumatoid arthritis patients Therapy of rituximab-refractory rheumatoid arthritis patients

A - Human Necessities

61

K

A61K 39/395 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2707791

A method is disclosed of treating a rituximab-refractory rheumatoid arthritis (RA) patient comprising administering an anti-CD20 antibody other than rituximab to the patient in an amount effective to treat the RA.

L'invention porte sur une méthode de traitement de patients atteints d'arthrite rhumatoïde et réfractaires au rituximab, consistant à leur administrer un anticorps anti CD20 autre que le rituximab, en quantité efficace pour traiter l'arthrite rhumatoïde.

Affiliated with

Also associated with

Rating

Therapy of rituximab-refractory rheumatoid arthritis patients does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy of rituximab-refractory rheumatoid arthritis patients, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy of rituximab-refractory rheumatoid arthritis patients will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2065250